For example, metformin inhibits ESCC carcinogenesis by inhibiting the AMPK/mTOR pathway, including activation of AMPK and inhibition of downstream molecules such as p-mTOR and cyclin D1 expression (Pelgrom et al., 2019). Here, MTOR is linked to esophageal squamous cell carcinoma.